Servier and GAIA extend their partnership to provide patients around the world with deprexis®, an internet-based cognitive behavioral therapy for depression
An innovative complementary way to treat depression adapted to patients’ needs
Suresnes, France and Hamburg, Germany – 14 February 2017 – Servier, an independent international pharmaceutical company, and GAIA, a global pioneer in digital therapy, announced today that they have signed a partnership to extend the marketing of deprexis®, an internet-based cognitive behavioral therapy to treat depression.
Although depression is a widely-spread pathology, with around 350 million people worldwide suffering from it (WHO), many patients do not get adequate treatment, for many different reasons including stigmatization.
deprexis® is a web-based EC- and FDA-cleared medical device developed by GAIA. The program provides the user with tailored therapeutic support by simulation of effective, up-to-date and personalized cognitive behavioral therapy interventions. This medical advancement provides a user-friendly interface associated with artificial intelligence software that ensures constant adaptation to the patient’s responses to questions asked, and to his/her needs while also keeping him/her engaged. The effectiveness of the program in reducing symptoms of depression has been shown in eight randomized controlled clinical trials with more than 2,000 patients, and was peer-reviewed by internationally known experts in the field of cognitive behavioral therapy.
deprexis® has been licensed to Servier for the German market since July 2015. It is available for patients in Germany under the label deprexis24®. The current agreement extends the exclusive marketing rights of Servier to all countries except US and Japan. Other countries will launch versions in local languages in the coming months.
“We are pleased that Servier has decided to extend our collaboration to other countries,” added Mario Weiss, CEO and founder of GAIA. “Their expertise in neuropsychiatry will be an asset to implement this treatment into actual clinical practice as there is not much of a precedent in this type of therapy.”
deprexis® is mainly an adjunct therapy, for patients with pharmacologic or psychotherapeutic treatments, but it could provide a useful solution for patients who would not go spontaneously to a therapist, or do not have access to one.
“This agreement fits perfectly with our patient-centered approach to healthcare”, commented Dr. Pierre Gaillard, Director of Global Marketing for Servier. “We are extremely open to complement our pharmacological portfolio of psychotropic drugs with innovative therapeutic solutions, for the benefit of patients.”
Servier is an international pharmaceutical company governed by a foundation and headquartered in Suresnes (France). With a strong international presence in 148 countries and a turnover of 4 billion euros in 2016, Servier employs 21 000 people worldwide. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular diseases, diabetes, cancers, immune-inflammatory diseases, and neurodegenerative diseases, as well as by its activities in high-quality generic drugs. Being completely independent, the Group reinvests 25% of turnover (excluding generics) in research and development and uses all its profits for growth.
GAIA is a global leader in digital therapeutics. With its stringent focus on research and development of evidence based online interventions the company continuously shifts benchmarks when it comes to effect sizes and safety profiles for digital therapeutics in neuroscience. With more than 100 experts in the field of Medicine, Psychology, Behavioral Medicine, Software Engineering as well as Regulatory and Market Access GAIA is a key partner in the development of next generation digital solutions to support and treat patients with a broad variety of medical conditions.
More information: gaia-group.com/en
Servier External Communications
Tel: +33 1 5572 6037
Dr. Matthias Zenker
Tel: +49 40 35 10 52 0